|
 |
COX-2
inhibitors: Balancing the hope, the hype, and the concern
When all is said and
done, the choice rests with the individual prescribing physician.
B.F. MANDELL
|
 |
Management
of primary headache: Serendipity and science
A capsule summary of
the current management of migraine, chronic tension headache, and
cluster headache.
G.D. SOLOMON
|
| |
Chronic
myelogenous leukemia: The news you have and haven’t heard
One major advance in
treating CML was widely publicized. Another, although equally
important, was not.
M.E. KALAYCIO
|
 |
Recognizing
and treating diabetic autonomic neuropathy
Strict glycemic
control can slow the onset of diabetic autonomic neuropathy and
sometimes reverse it. Other treatments address specific symptoms.
A.I. VINIK and T. ERBAS
|
| |
Role
of alendronate and risedronate in preventing and treating
osteoporosis
A review of the
efficacy and use of the two oral bisphosphonates approved for
preventing and treating osteoporosis.
M.L. PETERS, M. LEONARD, and A.A. LICATA
|
 |
A
44-year-old man with a pruritic skin rash
Questions and answers
on the visible signs of diseases.
R. BARGOUT and A. MALHOTRA
|
 |
 Brief answers to specific clinical
questions |
How
often are atrial septal defects associated with thromboembolism?
When should they be looked for?
In the absence of
other causative conditions, an atrial septal defect may be
presumed to be the underlying cause of a stroke, especially in
younger patients.
W.A. JABER and A.L. KLEIN
|
 |
COX-2
inhibitors and cardiovascular risk: Point and counterpoint
Even if we do not
know with certainty whether COX-2 inhibitors increase the risk of
cardiovascular events, we need to incorporate this concern into
our practice.
B.F. MANDELL
|
| POINT
AND COUNTERPOINT
........................................................................................... |
COX-2
inhibitors and cardiovascular risk: The data are inconclusive and
these drugs are needed
Unless a clear
cause-and-effect relationship can be proved between COX-2
inhibitors and cardiovascular events, we should go on using these
drugs.
J. LIPANI
|
| POINT
AND COUNTERPOINT
........................................................................................... |
COX-2
inhibitors and cardiovascular risk: We defend our data and suggest
caution
Our study had
limitations, but we believe our hypothesis is plausible, our
methods were valid, and our conclusions are sound.
D. MUKHERJEE, S.E. NISSEN, and E.J. TOPOL
|
GP IIb/IIIa drugs: What the latest trials show
